Abstract
Background: Hypertension is a health problem that is a challenge worldwide. Several treatments are currently being developed to treat hypertension, namely by giving Renin Inhibitor (RI) and Angiotensin-Converting Enzyme Inhibitor (ACE-I) drugs. The examples of each drug class are Aliskiren (RI) and Ramipril (ACE-I). The controversy over which drug Aliskiren from the RI group and Ramipril from the ACE-I group is still ongoing and needs to be resolved. Aims: This meta-analysis was conducted to compare the side effects experienced by patients treated with Aliskiren and Ramipril to reduce blood pressure. Methods: The search for published scientific articles was carried out systematically using the Preferred Reporting, Items for Systematic Review, and Meta-Analysis (PRISMA) method. The search was conducted using the Pubmed and Cochrane library databases published from 2005 to December 2021 regarding the comparison of side effects of giving Aliskiren with Ramipril in hypertensive patients Results: We found systematically all randomized trials whose effects were compared presenting Aliskiren with Ramipril in hypertensive patients. Five studies were included with a total of 3,381 patients randomized. Aliskiren therapy had more dominant side effects than Ramipril therapy. The side effects of Aliskiren were dizziness (OR 0.97, 95% CI 0.70-1.34; P=0.57; I2=0%), headache (OR 1.02, 95% CI 0.79-1.33; P= 0, 28; I2=21%) and cough (OR 0.30, 95% CI 0.21-0.42; P=0.37; I2=7%). Meanwhile, the side effects of ramipril were diarrhea (OR 1.08, 95% CI 0.53-2.20; P=0.10; I2=51%) and nasopharyngitis (OR 1.13, 95% CI 0, 78-1.63; P=0.80; I2=0%) Conclusions: Aliskiren and Ramipril therapy both gave therapeutic effects in the form of dizziness, headache, cough, diarrhea, and nasopharyngitis. Some of the more dominant side effects found in patients receiving Aliskiren therapy were dizziness, headache, and cough. Meanwhile, diarrhea and nasopharyngitis were more frequently found in patients receiving Ramipril therapy.
Concepts :
Access to Document
10.1097/01.hjh.0000832952.47063.64SDGs
Citations by Year
| Year | Count |
|---|---|
| 2022 | 1 |